FRESCO-2: A global phase 3 study of the efficacy and safety of fruquintinib in patients (pts) with metastatic colorectal cancer (mCRC)
Arvind Dasari, James Yao, Alberto Sobrero, Takayuki Yoshino, William Schelman, Shivani Nanda, Caly Chien, Su-Fen
London: Thursday, December 31, 2020: Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return:
1.
Name of applicant:
Hutchison China MediTech
London: Thursday, December 31, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at December 31, 2020, the issued share capital of Chi-Med consisted of 727,722,215 ordinary shares of US$0.10 e
London: Tuesday, December 15, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) announces that on December 14, 2020, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General
标题：
Results from a Phase 1 Dose Escalation Study of HMPL-689, a Selective Oral Phosphoinositide 3-Kinase-Delta Inhibitor, in Chinese Patients with relapsed/refractory (R/R) Lymphoma
选择性口服磷脂酰肌醇3-激酶亚型
London: Monday, November 30, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at November 30, 2020, the issued share capital of Chi-Med consisted of 727,702,215 ordinary shares of US$0.10 eac
London: Friday, November 27, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) was notified that CK Hutchison Holdings Limited (“CK Hutchison”) shareholding[1] in Chi-Med remains unchanged, at 332,478,770 ordinary shares
London: Friday, October 30, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at October 30, 2020, the issued share capital of Chi-Med consisted of 711,025,545 ordinary shares of US$0.10 each,
London: Wednesday, September 30, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at September 30, 2020, the issued share capital of Chi-Med consisted of 710,785,545 ordinary shares of US$0.1
London: Friday, August 28, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at August 28, 2020, the issued share capital of Chi-Med consisted of 710,594,765 ordinary shares of US$0.10 each, w
Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, August 12, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) announces that on August 11, 2020, it granted share options under the Share Option Scheme conditionally adopte
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:
Hutch
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:
Hutch
London: Tuesday, July 7, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) was notified that CK Hutchison Holdings Limited (“CK Hutchison”) shareholding1 in Chi-Med remains unchanged, at 332,478,770 ordinary shares of par v
London: Monday, June 29, 2020: Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return:
1.
Name of applicant:
Hutchison China MediTech Limite
London: Friday, June 26, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) will be announcing its interim results for the six months ended June 30, 2020 on Thursday, July 30, 2020 at 12:00 noon British Summer Time (BST) (7:00 p